Zhi Tong Cai Jing·2025-11-03 02:40Core Viewpoint - Chuangli Medical (01858) has seen a significant stock price increase of over 9%, with a cumulative rise of nearly 25% following its earnings report, indicating strong market confidence in the company's performance and growth prospects [1] Financial Performance - For the first three quarters, the company reported revenue of 756 million yuan, representing a year-on-year growth of 48.75% [1] - The net profit for the same period reached 192 million yuan, showing a substantial year-on-year increase of 213.21% [1] - In the third quarter alone, revenue was 268 million yuan, reflecting a remarkable year-on-year growth of 109.51% [1] - The net profit attributable to the parent company in the third quarter was 77.06 million yuan, marking a turnaround from losses to profitability [1] Market Expansion and Competitive Advantage - Huatai Securities attributes the rapid growth in the third quarter to the company's steady progress in international market expansion, with export revenue continuing to rise [1] - The company has successfully passed CE annual system audits and supervision audits for its hip, knee, and spine product lines, and its knee prosthesis system has received FDA 510(K) approval, highlighting its technological advantages and strong international market competitiveness [1] - The ongoing expansion of overseas business is expected to contribute significantly to revenue growth, with a positive outlook for sustained rapid growth in overseas performance through 2025 [1]